Source:http://linkedlifedata.com/resource/pubmed/id/16179866
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2005-9-23
|
pubmed:abstractText |
The Fas/FasL signalling system plays an important role in chemotherapy-induced apoptosis in several different cell types. After interferon-gamma (IFN-gamma) treatment, we have previously reported a significant increase in Fas expression in oral malignant melanoma cell lines (MMN9, PMP, MAA, HMG) in vitro, and combination therapy using IFN-gamma and anti-Fas antibody (CH-11) has shown a synergistic anti-proliferative effect in MMN9 cells. There have been several in-vitro studies using CH-11, but there are few reports of its anti-tumour effect in vivo. In this study, we investigated experimental therapy using anti-Fas antibody against MMN9 in vivo in a mouse model, and histologically examined tumour tissue removed from BALB/c nude mice. Animals that received both IFN-gamma and CH-11 showed a 53.8% increase in anti-tumour effect (P=0.0018) 20 days after the first administration. In the histological study, the combined administration group tested positive in terminal deoxynucleotidyl transferase-mediated nick end labelling staining, and showed significantly increased levels of Fas expression on immunostaining compared with the vehicle group. These results show the efficacy of anticancer therapy using IFN-gamma and anti-Fas antibody via the modulation of Fas-mediated apoptosis. Moreover, inhibition of IFN-gamma/CH-11-induced apoptosis with a general caspase inhibitor (benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone) reduced cell death significantly in vitro. Bcl-2 cleavage did not occur under these conditions, suggesting a relationship between caspase activation and Bc1-2 cleavage in MMN9 cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD95,
http://linkedlifedata.com/resource/pubmed/chemical/CH-11 anti-fas antibody, human,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0960-8931
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
393-400
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:16179866-Animals,
pubmed-meshheading:16179866-Antibodies,
pubmed-meshheading:16179866-Antigens, CD95,
pubmed-meshheading:16179866-Apoptosis,
pubmed-meshheading:16179866-Cell Line, Tumor,
pubmed-meshheading:16179866-Female,
pubmed-meshheading:16179866-Humans,
pubmed-meshheading:16179866-Immunotherapy,
pubmed-meshheading:16179866-Interferon-gamma,
pubmed-meshheading:16179866-Melanoma,
pubmed-meshheading:16179866-Mice,
pubmed-meshheading:16179866-Mice, Inbred BALB C,
pubmed-meshheading:16179866-Mice, Nude,
pubmed-meshheading:16179866-Mouth Neoplasms,
pubmed-meshheading:16179866-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:16179866-Xenograft Model Antitumor Assays
|
pubmed:year |
2005
|
pubmed:articleTitle |
Experimental therapy using interferon-gamma and anti-Fas antibody against oral malignant melanoma cells.
|
pubmed:affiliation |
Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Mie University, Japan. t-kamei@clin.medic.mie-u.ac.jp
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|